A PfRH5-Based Vaccine Is Efficacious against Heterologous Strain Blood-Stage Plasmodium falciparum Infection in Aotus Monkeys

Alexander D. Douglas,1,* G. Christian Baldeviano,2 Carmen M. Lucas,2 Luis A. Lugo-Roman,2 Cécile Crosnier,3 S. Josefín Bartholdson,3 Ababacar Diouf,4 Kazutoyo Miura,4 Lynn E. Lambert,5 Julio A. Ventocilla,5 Karina P. Leiva,2 Kathryn H. Milne,1 Joseph J. Illingworth,1 Alexandra J. Spencer,1 Kathryn A. Hjerrild,1 Daniel G.W. Alanine,1 Alison V. Turner,1 Jeromy T. Moorhead,2 Kimberly A. Edgel,2 Yimin Wu,5 Carole A. Long,4 Gavin J. Wright,3 Andrés G. Lescano,2 and Simon J. Draper1

1Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK
2US Naval Medical Research Unit No. 6 (NAMRU-6), Lima, Peru
3Wellcome Trust Sanger Institute, Cambridge CB10 1HH, UK
4Laboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA
5Laboratory of Malaria Immunology and Vaccinology, NIAID/NIH, Rockville, MD 20852, USA

*Correspondence: sandy.douglas@ndm.ox.ac.uk
http://dx.doi.org/10.1016/j.chom.2014.11.017
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).

SUMMARY

Antigenic diversity has posed a critical barrier to vaccine development against the pathogenic blood-stage infection of the human malaria parasite Plasmodium falciparum. To date, only strain-specific protection has been reported by trials of such vaccines in nonhuman primates. We recently showed that P. falciparum reticulocyte binding protein homolog 5 (PfRH5), a merozoite adhesin required for erythrocyte invasion, is highly susceptible to vaccine-inducible strain-transcending parasite-neutralizing antibody. In vivo efficacy of PfRH5-based vaccines has not previously been evaluated. Here, we demonstrate that PfRH5-based vaccines can protect Aotus monkeys against a virulent vaccine-heterologous P. falciparum challenge and show that such protection can be achieved by a human-compatible vaccine formulation. Protection was associated with anti-PfRH5 antibody concentration and in vitro parasite-neutralizing activity, supporting the use of this in vitro assay to predict the in vivo efficacy of future vaccine candidates. These data suggest that PfRH5-based vaccines have potential to achieve strain-transcending efficacy in humans.

INTRODUCTION

The development of a highly effective and deployable malaria vaccine remains an urgent priority for improving global public health. Despite recent strides in disease prevention and control, the Plasmodium falciparum human malaria parasite continues to exert a huge toll in terms of morbidity and mortality (Murray et al., 2012). The most advanced malaria subunit vaccine, a virus-like particle known as RTS,S, has shown only modest efficacy in young children in Phase III clinical trials (Agnandji et al., 2012), and thus new approaches are urgently needed (Moorthy et al., 2013). RTS,S induces antibodies that reduce liver infection by the parasite (Foquet et al., 2014). An alternative and complementary strategy is to vaccinate against the subsequent blood-stage infection (which causes clinical disease and against which natural immunity is slowly acquired). Such a vaccine could prevent death and reduce incidence of disease, parasitemia, and onward transmission (Hill, 2011). However, despite 25 years of development, vaccine candidates targeting P. falciparum’s asexual blood stage have failed to overcome the challenge posed by the parasite’s antigenic diversity. Two of the most critical roadblocks have included exceptionally high thresholds for protective levels of antibody against known target antigens, coupled with problematic levels of antigen polymorphism. To date, no vaccine candidate has overcome these hurdles to achieve in vivo protection in human clinical trials (Goodman and Draper, 2010; Thera et al., 2011). In previous nonhuman primate (NHP) studies (which provide the only opportunity to study the effect of vaccines against an uninterrupted P. falciparum blood-stage infection), blood-stage vaccine candidates have proven protective only against vaccine-homologous parasite lines, and only when administered with non-human-compatible adjuvants (Dutta et al., 2009; Lyon et al., 2008).

P. falciparum reticulocyte-binding protein homolog 5 (PfRH5) is a recently identified merozoite protein, secreted from the apical organelles of the parasite during the red blood cell (RBC) invasion process (Baum et al., 2009). In vitro data have identified PfRH5 as the highest priority target in the blood-stage malaria vaccine field for over a decade (Douglas et al., 2011). Antibodies induced by PfRH5 vaccination of mice and rabbits overcome the two major difficulties outlined above: (i) antibodies can block erythrocyte invasion to high efficiency (with lower EC₅₀ in terms of µg/ml antigen-specific antibody than against all other known antigens) (Douglas et al., 2014; Miura et al., 2009; Williams et al., 2012) and (ii) most importantly, these antibodies cross-inhibit all P. falciparum lines and field isolates tested to date...
The PfRH5 protein is now known to mediate a critical non-redundant interaction with the human RBC surface protein basigin during invasion (Crosnier et al., 2011). The PfRH5 gene is also refractory to genetic deletion (Baum et al., 2009; Hayton et al., 2008), unlike many other blood-stage antigens, confirming the essential nature of its function. In the context of natural infection, PfRH5 does not appear to be a dominant target of naturally acquired immune responses in endemic populations (Douglas et al., 2011; Tran et al., 2014; Villasis et al., 2012), but when detected, such antibody responses correlate with protective clinical outcome (Tran et al., 2014), and affinity-purified anti-PfRH5 human antibodies can neutralize parasites in vitro (Patel et al., 2013; Tran et al., 2014). The high degree of PfRH5 sequence conservation is thus associated with low-level natural immune pressure, but also functional constraints linked to basigin binding. Importantly, it has been shown that minimal amino acid substitutions in PfRH5 account for loss of basigin binding and/or host RBC tropism (linked to binding basigin orthologs from other species), suggesting the antigen may not easily escape vaccine-induced immune pressure (Hayton et al., 2008, 2013; Wanaguru et al., 2013). However, to date, no study has assessed the protective efficacy of PfRH5-based vaccines in vivo, and it remains unclear whether the encouraging observations made in vitro using an assay of parasite neutralization will translate into biological relevance.

The PfRH5 protein is now known to mediate a critical non-redundant interaction with the human RBC surface protein basigin during invasion (Crosnier et al., 2011). The PfRH5 gene is also refractory to genetic deletion (Baum et al., 2009; Hayton et al., 2008), unlike many other blood-stage antigens, confirming the essential nature of its function. In the context of natural infection, PfRH5 does not appear to be a dominant target of naturally acquired immune responses in endemic populations (Douglas et al., 2011; Tran et al., 2014; Villasis et al., 2012), but when detected, such antibody responses correlate with protective clinical outcome (Tran et al., 2014), and affinity-purified anti-PfRH5 human antibodies can neutralize parasites in vitro (Patel et al., 2013; Tran et al., 2014). The high degree of PfRH5 sequence conservation is thus associated with low-level natural immune pressure, but also functional constraints linked to basigin binding. Importantly, it has been shown that minimal amino acid substitutions in PfRH5 account for loss of basigin binding and/or host RBC tropism (linked to binding basigin orthologs from other species), suggesting the antigen may not easily escape vaccine-induced immune pressure (Hayton et al., 2008, 2013; Wanaguru et al., 2013). However, to date, no study has assessed the protective efficacy of PfRH5-based vaccines in vivo, and it remains unclear whether the encouraging observations made in vitro using an assay of parasite neutralization will translate into biologically relevant antiparasitic activity. This question is of particular importance, given the current lack of a clear correlate of vaccine efficacy against blood-stage infection in humans (Duncan et al., 2012) and the need to design improved strain-transcending malaria vaccines that can be progressed to clinical development.

In this study, we quantitatively assessed the immunogenicity of PfRH5-based vaccines delivered to Aotus monkeys by three different immunization regimens, including protein-in-adjuvant formulations (de Cassan et al., 2011) and an adenovirus/poxvirus vectored platform previously optimized for Phase I/IIa clinical development (Draper et al., 2008; Sheehy et al., 2012). We also evaluated the protective efficacy of these vaccines against a stringent vaccine-heterologous P. falciparum challenge (Stowers and Miller, 2001). This study enabled us to monitor the ability of PfRH5-based vaccines to both control and clear a virulent blood-stage infection. We report that significant protection against challenge with heterologous-strain blood-stage P. falciparum can be achieved in vivo by these vaccines, including when using the human-compatible viral vectored delivery platform. This protection was associated with anti-PfRH5 antibody concentration and parasite-neutralizing activity, supporting the use of this assay to predict the in vivo efficacy of future vaccine candidates. These results suggest that PfRH5-based vaccines have the potential to achieve strain-transcending efficacy in humans.

RESULTS

Evaluation of PfRH5 Vaccine Efficacy in Aotus Monkeys

31 Aotus nancymae monkeys were randomized to groups that received protein-in-adjuvant and/or viral vectored vaccination regimens targeting either P. falciparum RH5 or apical membrane antigen 1 (PfAMA1), a well-studied comparator antigen that elicits strain-specific antibodies (Dutta et al., 2008; Remarque et al., 2008; Thera et al., 2011) (Figure 1A). The PfRH5 protein immunogen was pure (Figure S1A) and shown to be correctly folded by demonstration of binding to its receptor, basigin (Crosnier et al., 2011) (Figure S1B). Group A received sham vaccines, chimpanzee adenovirus serotype 63 (ChAd63) expressing Renilla luciferase (RLuc) prime, PBS with Abisco-100 adjuvant boost; Group B received PfRH5 protein with complete or incomplete Freund’s adjuvant (CFA, IFA); Group C received ChAd63 expressing PfRH5 prime, PfRH5 protein with Abisco-100 boost; Group D received ChAd63-PfRH5 prime, modified vaccinia virus Ankara (MVA) expressing PfRH5 boost; and Group E received ChAd63-PfAMA1 prime, PfAMA1 protein with Abisco-100 boost. The ChAd63-MVA vaccine delivery platform used here has now been progressed to human clinical testing for a wide variety of difficult disease targets, including malaria, HIV-1, and hepatitis C virus (de Cassan and Draper, 2013; Draper and Heeney, 2010), while the use of mixed-modality adenoviral priming-protein-boost regimens has shown promise in small animals as well as initial clinical studies (de Cassan et al., 2011; Draper et al., 2010) (Hodgson et al., 2014). In the case of this study, the PfRH5 vaccines encoded the 3D7 allele of the antigen, while for PfAMA1 the ChAd63 vector expressed two alleles of the antigen (3D7 and FVO), and FVO allele PfAMA1 protein was used for the boost. The Group A sham-vaccinated animals served as protocol-specified infectivity controls in order to confirm consistent infection by the FVO parasite inoculum and its appropriate adaptation to growth in Aotus.

To evaluate the protective efficacy of the vaccines, animals were challenged 15 days after the final vaccination by intravenous administration of 10^5 PfRH5-vaccine-heterologous FVO strain P. falciparum infected red blood cells (iRBC) taken from a donor monkey. The parasitemia (Figures 1B–1F) and hematocrit (Hct) (Figures S1C–S1G) in the challenged animals were monitored over time. Challenge infection with this parasite line has proven highly virulent in Aotus nancymaeae over the course of numerous studies, requiring treatment in all control animals administered complete Freund’s adjuvant without a blood-stage vaccine antigen (n = 55, Table S1 and Supplmentary Information). In contrast, none of the animals immunized here with PfRH5 protein in Freund’s adjuvant (Group B) required treatment. Efficacy in this group was significant, both comparing treatment status versus adjuvant-matched historical controls (the protocol-specified primary analysis for this group; Kendall’s τ_B = 0.703, p < 0.001 versus historical controls) and comparing log_{10} cumulative parasitemia (LCP) up to the first day on which an animal was treated (day 10) versus Group A in the current study (p = 0.002 by Mann-Whitney test, Figure 1G). No parasites were seen by thin-film microscopy at any point in two of the animals, with only a single parasite seen on one occasion in a third animal; the remaining three animals self-cured after periods of microscopically patent parasitemia at levels <10,000 parasites/μl (p/μl) (Figure 1C). To our knowledge, such robust protection has not been observed even after vaccine-homologous challenge of Aotus immunized with P. falciparum AMA1, merozoite surface protein 1 (PfMSP1), PfMSP3, or the erythrocyte binding antigen 175 kDa (PfEBA175) formulated with Freund’s adjuvant (Hisaeda et al., 2002; Jones et al., 2001; Stowers et al., 2001, 2002). Here, the PfRH5 antigen of the challenge strain, FVO,
Figure 1. PfRH5 Vaccines Protect against P. falciparum Challenge

(A) Vaccination regimens. Immunizations were performed by the intramuscular route on days 0 and 54, with the exception of those containing Freund’s adjuvant, which were given subcutaneously on days 0, 26, and 54. Doses used were $5 \times 10^9$ infectious units (ifu) for ChAd63 vaccines, $2 \times 10^8$ plaque-forming units (pfu) for MVA, 50 $\mu$g for protein vaccines, 250 $\mu$l for Freund’s adjuvant, and 48 $\mu$g for Abisco-100.

(B–F) Time course of parasitemia for individual animals in Group A (B), Group B (C), Group C (D), Group D (E), and Group E (F). Upper horizontal dashed line indicates the 200,000 p/µl threshold for initiation of antimalarial treatment (Rx) because of hyperparasitemia; lower horizontal dotted line indicates absence of thin-film detectable parasites. P indicates treatment due to hyperparasitemia; A indicates treatment due to anemia; SPx3 at day 28 in Group B indicates cessation of follow-up of three animals that had been microscopically subpatent since day 4; SC indicates self-cure in animals that had experienced sustained parasitemia; + indicates a single animal found dead on day 16; occasional unexpected deaths have previously been recorded among Aotus both before and during P. falciparum challenge (Darko et al., 2005; Hisaeda et al., 2002; Singh et al., 2006).

(G) Cumulative parasitemia up to day 10, the first day on which an animal was treated. *p < 0.01 versus Group A by Mann-Whitney test performed with Bonferroni correction for multiple comparison (this was the prespecified primary analysis for Groups C–E; secondary analysis for Group B).

(H) Kaplan-Meier plot of percentage untreated survival by group. Symbols are as in (B)–(F). Comparing time to treatment in each group to Group A was done by Mann-Whitney test with Bonferroni correction for multiple comparison, p = 0.02 for each of Groups B and D.

See also Figures S1 and S5 and Table S1.
Figure 2. Lack of Relationship between ELISpot and ICS Responses and Challenge Outcome

(A–C) Relationships between challenge outcome (LCP) and PfRH5-specific ELISpot responses (A), IFN-γ+CD4+ T cell responses (B), and IFN-γ+CD8+ T cell responses (C) in PfRH5-vaccinated animals (n = 17 for ELISpot, n = 16 for ICS; Groups B, C, D, excluding the two animals for which ELISpot results were not obtained and the three animals for which ICS results were not obtained). All panels plot responses after subtraction of responses in negative control unstimulated wells. Dashed line marked “< Background” indicates responses of less than the mean plus three standard deviations (SD) of the apparent response in Group A animals. (D) Lack of statistically significant Spearman’s rank correlation between ELISpot and ICS-measured immunological parameters and outcome parameters (LCP or peak parasitemia; no Bonferroni correction was made). Measurements that did not exceed background (defined as above) were treated as tied observations. See also Figure S2.

Significant vaccine efficacy was also observed in the animals immunized with human-compatible ChAd63-MVA PfRH5 vaccines (Group D), as judged using the prespecified primary endpoint for Groups C–E of LCP up to day 10 as compared to Group A (Figure 1G; p = 0.007 by Mann-Whitney test with Bonferroni correction for multiple comparison). Similar to Freund’s adjuvant, there are abundant pre-existing data across multiple species to demonstrate that there is no nonspecific effect of the viral vector vaccines used in Group D upon the rate of Plasmodium blood-stage infection, including for P. falciparum in malaria-challenged humans as compared to unvaccinated infectivity controls (Ewer et al., 2013; Sheehy et al., 2012), as well as in three rodent malaria species: P. yoelii, P. berghei, or P. chabaudi (Biswas et al., 2012; Goodman et al., 2013). There was also no nonspecific effect of vaccination with COPAK (a poxvirus similar to the MVA) upon the course of P. knowlesi parasitemia in rhesus macaques (Weiss et al., 2007). However, as is typical in this model, a number of animals that developed but controlled relatively high-level parasitemia in Groups C and D subsequently required treatment due to anemia (Figures 1H and S1C–S1G), the severity and timing of which correlated with the level and timing of peak parasitemia (Figures S2H–S2J). Most importantly, unlike previous trials of a human-compatible blood-stage vaccine delivery platform in this model, self-cure of infection without severe anemia was observed in 4/6 animals in the ChAd63-MVA PfRH5 group and 1/7 in the ChAd63-Protein PfRH5 group (Figures 1D, 1E, and 1H). The four self-curing animals in the ChAd63-MVA PfRH5 group experienced median peak parasite density of 48,000 p/µL (median peak percentage parasitemia 0.9%) and were afebrile and clinically well throughout.

Immunologic Correlates of Protection

The rationale for the development of these PfRH5 vaccines was the observation that PfRH5-specific antibodies could achieve high levels of parasite-neutralizing in vitro growth inhibitory activity (GIA) (Bustamante et al., 2013; Douglas et al., 2011; Williams et al., 2012). We therefore hypothesized prior to the trial that protection achieved by PfRH5 vaccines would be associated with anti-PfRH5 antibody concentrations and in vitro GIA, but not necessarily with cellular responses against PfRH5. To test this hypothesis, we initially assessed humoral and cellular immune responses to ELISA, interferon-γ (IFN-γ) ELISpot, and intracellular cytokine staining (ICS) assays.

Antigen-specific T cell responses to a subunit vaccine have rarely been measured in Aotus, but we were able to detect PfRH5 and PfAMA1-specific IFN-γ-producing PBMCs by ELISpot (Figures S2A–S2C) and resolve these into CD4+ and CD8+ T cells by ICS (Figures S2D–S2G). There was no correlation between ELISpot or ICS responses and LCP or peak parasitemia (Figures 2A–2D).

The vaccines also induced substantial PfRH5-specific antibody responses, as measured by ELISA with conversion into absolute antigen-specific antibody concentrations achieved via surface plasmon resonance (SPR) calibration-free concentration analysis (CFCA) (Williams et al., 2012) (Figures 3A, S3, and S4A–S4F). Geometric mean day-of-challenge (DoC) PfRH5-specific antibody concentrations achieved were 700 µg/ml in Group B (PfRH5 protein in Freund’s adjuvant), 54 µg/ml in Group C (ChAd63-Protein PfRH5), and 320 µg/ml in Group D (ChAd63-MVA PfRH5); the corresponding geometric mean anti-PfAMA1 (FVO allele)-specific antibody concentration in Group E was 140 µg/ml. There was a strong and statistically significant
correlation between anti-PfRH5 antibody concentration and challenge outcome (Figures 3B–3D). These correlations were maintained when the analysis was conducted among animals within Groups B and D (Figures S4G and S4H). Given that these animals serve as matched controls for each other within a group, such a correlation would be unlikely if protection was attributable to a nonspecific effect of the adjuvant or the viral vaccine vector.

In vivo growth inhibition was also calculated (IVGI; the percentage reduction in the parasite multiplication rate (PMR) in each animal relative to the mean in the control group, as has been previously described; Mahdi Abdel Hamid et al., 2011). Using nonlinear least-squares regression, the concentration of anti-PfRH5 immunoglobulin G (IgG) required to achieve 50% IVGI (IVGI EC$_{50}$) was estimated at 185 μg/ml (95% CI 100–330 μg/ml, using data from Groups B–D). The relationship between PfAMA1–specific antibody concentration and IVGI was suggestive of a higher IVGI EC$_{50}$ for anti-PfAMA1 IgG than for anti-PfRH5 IgG (Figure 3D). These in vivo growth inhibition data are thus in line with previous in vitro GIA data using purified antigen–specific anti-PfRH5 and anti-PfAMA1 IgG from rabbits and humans (Miura et al., 2009; Tran et al., 2014), suggesting that parasites are quantitatively more susceptible to anti-PfRH5 than to anti-PfAMA1 antibodies.

We subsequently assessed the functional ability of the vaccine-induced antibody responses to neutralize parasites in the GIA assay. The ability of a range of concentrations of protein G-purified total IgG to neutralize FVO (challenge-strain) parasites was assessed (Figure 4A). There was a strong and statistically significant relationship between GIA at 2.5 mg/ml total IgG and IVGI, the protocol–specified primary analysis for an immunological correlate of protection (Figure 4B). Immunological correlates of vaccine-induced protection against other pathogens are commonly the attainment of a particular level of in vitro activity at a certain serum dilution titer (Plotkin, 2010). Here, we observed that the total plasma IgG concentration of animals immunized with different regimes differed substantially (Figure 4C). We therefore calculated a GIA$_{50}$ titer, defined as the dilution factor from the plasma IgG concentration to the IgG concentration achieving 50% GIA. GIA$_{50}$ titer was closely associated with challenge outcome (Figure 4D), with attainment of a GIA$_{50}$ titer exceeding five appearing predictive of untreated survival.

**Impact of Infection on Vaccine-Induced Responses**

We also monitored immune responses in the period following the challenge infection. Consistent with the poor immunogenicity of PfRH5 in the context of natural infection (Douglas et al., 2011; Tran et al., 2014; Villasis et al., 2012), the effect of parasite exposure on PfRH5–specific antibody levels was variable (Figure 5A) when assessing the day of challenge (day 69) versus the end of the challenge follow-up period (day 107). In contrast, median anti-PfAMA1 IgG levels increased across all the groups, but most notably in Group E (Figure 5B). Nearly every animal experiencing a patent infection seroconverted to the 19 kDa C terminus of PfMSP1 (PfMSP1$_{19}$; Figure 5C), consistent with the abundant and immunodominant nature of this merozoite surface antigen, supported by similar data from controlled human malaria infection (CHMI) studies in malaria-naive adult volunteers (Elias et al., 2014). Changes in GIA measured at a constant total IgG concentration of 2.5 mg/ml in the same period were small, with no significant change in PfRH5–vaccinated, PfAMA1–vaccinated, or sham–vaccinated animals (median changes of −7%, −3%, and 6%; $p = 0.21, 0.81$, and 0.14, respectively, by Wilcoxon signed–rank test). Nonetheless, GIA$_{50}$ titers increased substantially in many cases, due to increases in total plasma IgG concentration after parasite exposure (Figures 5D and 5E). Follow–up of animals to day 230 (161 days after challenge)
Figure 4. Attainment of 50% GIA at a Sub-physiological IgG Concentration Predicts Protection

(A) The in vitro GIA of purified IgG (DoC time point) was assessed against FVO strain parasites for all animals at a fixed concentration of 2.5 mg/ml. Percent GIA is reported following a single cycle of parasite growth. For animals in Groups B, C, and D, the assays were repeated with a dilution series of the purified IgG. The results for each individual animal are shown.

(B) Prespecified primary analysis for an immunological correlate of protection: relationship between percent GIA using 2.5 mg/ml purified IgG in the assay and the percent IVGI modeled from the parasitemia data. Across all animals (n = 31), Spearman’s rs = 0.86, p < 0.0001; among non-control vaccinated animals only (Groups B–E, n = 25, as shown), rs = 0.92, p < 0.0001. The dashed lines identify animals in the top right quadrant that did not require treatment following challenge. GIA was predictive of outcome independent of group allocation (p = 0.004 by likelihood-ratio test comparing a bivariate model relating IVGI with group versus a multivariate model relating IVGI with group plus GIA at 2.5 mg/ml).

(C) The plasma concentration of IgG in mg/ml was assayed at the DoC time point. Individual results and group medians are reported. See also Figure S5.

(D) GIA50 titers were calculated for Groups B, C, and D (by dividing the plasma total IgG concentration by the total IgG GIA EC50) and is plotted against peak parasitemia. Three animals in Group C, which all required treatment, did not achieve 50% GIA at 2.5 mg/ml and were assigned tied GIA50 titers of 1. Spearman’s rank correlation coefficient is shown.

DISCUSSION

Overall, these results demonstrate that PFRH5-based vaccines have the potential to overcome the shortcomings of previous blood-stage vaccines against *P. falciparum* (Wright and Rayner, 2014). The attainment of cross-strain protection in vivo by an antigen selected on the basis of its ability to induce cross-strain GIA in vitro strongly hints that the relationship between GIA and protection is causal, encouraging the continued use of the assay for candidate vaccine selection. Our findings are also consistent with previous data linking protection with the attainment of 60% GIA against the challenge strain at 2.5 mg/ml total IgG, suggesting that the quantitative relationship between GIA and protection may be roughly similar for different antigens (Singh et al., 2006). Importantly, the efficacy observed here also would have been readily detectable in a Phase IIa CHMI clinical trial (Figures S5B and S5C). These data thus support the assertion that an efficacious blood-stage vaccine candidate should be able to demonstrate in vivo biological effects in CHMI trials prior to field trials (Sheehy et al., 2013).

Protection in this study appeared to be mediated by pre-formed anti-PFRH5 antibody present at the time of infection, as distinct from a recall response against PFRH5 after challenge. Antigen-specific antibody concentrations exceeding 100 μg/ml have been attained in humans by other malaria vaccines including RTS,S and those targeting PfAMA1 (Kester et al., 2009; Spring et al., 2009), but long-term maintenance of such high-level responses may be challenging, particularly if *P. falciparum* infection does not appreciably boost vaccine-induced anti-PFRH5 responses. We have recently demonstrated that antibodies of other specificities can act synergistically with anti-PFRH5 antibodies in GIA assays, thus supporting an ongoing strategy to achieve protection with substantially lower and more easily maintained antibody concentrations (Williams et al., 2012).

Like the functionally critical surface proteins of other challenging vaccine targets, such as HIV-1 and influenza virus, the immunodominant antigens of *Plasmodium* spp. are highly variable (Riley and Stewart, 2013). PFRH5 is also functionally critical, but analogous to the pre-erythrocytic malaria antigen circumsporozoite protein (the basis of the RTS,S vaccine), the response to it in the context of infection is unlikely to be of sufficient magnitude to be a substantial contributor to natural immunity (Douglas et al., 2011; Murungi et al., 2013; Tran et al., 2014). Although this immune evasion strategy is clearly successful in permitting *P. falciparum* to establish repeated and chronic infections, it has left a conserved whole-protein target that appears more susceptible to subunit vaccination than the conserved epitopes presented by HIV-1 and influenza.

The clinical implications of these data for PFRH5-based vaccines remain unknown for now and will require clinical trials to assess immunogenicity and efficacy in humans (Figure S5D). However, given the attainment of an unprecedented level of protection in a stringent model, this study has clearly demonstrated
that the problem of interstrain blood-stage antigen variation is tractable. It is worth noting that the FVO strain of \textit{P. falciparum} has been selected for rapid growth and virulence in \textit{Aotus} monkeys; as a result, it is considerably more virulent in these animals (essentially universally fatal in untreated animals) than is the case for \textit{P. falciparum} in humans (in which the probability of severe disease is thought not to exceed 15% per episode even in malaria-naive infants) (Collins et al., 1994; Gupta et al., 1999). Moreover, having defined two significant correlates of protection, it will now be possible to rationally improve PfRH5-based immunogens and their delivery in order to maximize functional antiparasitic immunity. The optimization of PfRH5 vaccine formulations to achieve and maintain the highest possible levels of antibody will also be a major focus of human clinical trials that should commence within the coming year, supported by a greater weight of preclinical evidence than any previous blood-stage vaccine candidate. In summary, this study provides the initial proof of concept in NHPs that the development of a strain-transcending blood-stage vaccine against \textit{P. falciparum} is possible and provides important insight into a correlate of protection against the human malaria parasite.

**EXPERIMENTAL PROCEDURES**

Full experimental methods are provided in detail in the Supplemental Information.

**Vaccines**

All PfRH5 vaccines were based upon the \textit{P. falciparum} 3D7 clone sequence. The production of recombinant MVA expressing full-length PfRH5 has previously been described (Douglas et al., 2011). For the current study, a ChAd63 vector expressing the same PfRH5 transgene was produced using previously described methods (Goodman et al., 2010). The production of the ChAd63 and protein PfAMA1 (FVO allele) vaccines have been reported elsewhere (Biswas et al., 2011; Kennedy et al., 2002). The PfRH5 3D7 protein was expressed and tested for basigin binding essentially as described (Crosnier et al., 2011).

**Animals, Immunizations, Challenge, and Sample Collection**

Adult female owl monkeys (\textit{Aotus nancymaae}) were housed at the US Naval Medical Research Unit No. 6 (NAMRU-6). Randomization to groups was stratified by pretrial weight. All immunizations were administered under ketamine anesthesia and performed by the intramuscular route (into the caudal quadriceps), with the exception of those containing Freund’s adjuvant, which were given subcutaneously (into the interscapular area). The study protocol was approved by NAMRU-6’s Institutional Animal Care and Use Committee (protocol number NAMRU-6 11-12), the Department of the Navy Bureau of Medicine and Surgery (NRD-748), the University of Oxford Animal Care and Ethical Review Committee, and the Institut Nacional de Recursos Naturales (INRENA) at the Peruvian Ministry of Agriculture.

15 days after the final vaccination, animals were challenged intravenously with $1 \times 10^7$ FVO-strain \textit{P. falciparum} iRBC taken from a donor monkey, as previously described (Stowers et al., 2001). From day 72, daily thin-film parasitemia quantification and alternate-day Hct measurements were conducted. Animals were treated (i) when parasite density reached $\geq 200,000/\mu L$, (ii) when Hct fell to $<25\%$, (iii) upon reaching challenge day 28 (C+28) if no parasites had been seen in the preceding week, or (iv) upon reaching C+38 (study day 107). Blood samples for immunological assays were collected from all animals’ saphenous veins under ketamine anesthesia. EDTA-anticoagulated blood was prepared using standard methods to obtain plasma and PBMC.

**Cellular Immune Assays**

Ex vivo IFN-\gamma ELISpot and ICS were performed essentially as previously described (Craper et al., 2010). Assays used frozen PBMC and pools of PfRH5 and PfAMA1 peptides.
ELISA, CFCA, and GIA

PIAMA1 ELISAs used the same recombinant PIAMA1 FVO protein as that used for immunization. The production of PIAMSP1α protein (QKNG allele) has been previously described (Goodman et al., 2010). Monobiotinylated PRR5H protein was produced for ELISAs by transient transfection of HEK293E cells (Durocher et al., 2002). The ELISA encoded the version of the PRR5H antigen expressed in the viral-vector vaccines (which lacks the CD4 d3+4 and His6 tags present in the protein vaccine). ELISAs were performed essentially according to published methodology (Sheehy et al., 2011). The OD-based ELISA results for PIAMA1 and PRR5H were converted to μg/ml using the results of CFCA analyses, similar to that previously described (Williams et al., 2012).

Assays of GIA were performed at the PATH-MVI GIA reference laboratory, NIAID, NIH, using purified total IgG, FVO strain P. falciparum parasites, and a previously published method (Miura et al., 2009). A single-lifecycle assay was performed, followed by growth quantification by colorimetric detection of parasite lactate dehydrogenase. For each sample achieving >50% GIA at 2.5 mg/ml, total IgG GIA EC50 was calculated in terms of total IgG concentration in the well by linear interpolation. The total IgG concentration in each plasma sample was measured using Protein A biosensors on a ForteBio instrument (ForteBio). For each animal achieving >50% GIA at 2.5 mg/ml, the GIA50 titer was then calculated by dividing the plasma total IgG concentration by the total IgG GIA EC50.

Analyses and Statistics

Throughout, all reported p values are for two-tailed tests. Vaccine efficacy endpoints were recorded, as used in a previous Aotus-P. falciparum challenge study (Lyon et al., 2009) and a study of P. knowlesi infection of rhesus macaques (Mahdi Abdel Hamid et al., 2011). Kendall’s tau-b was used to test a null hypothesis of equivalent outcome between Group B and historical Freund’s control animals (see Table S1 and Supplemental Information) using the ordinarily ranked outcome data. As a secondary efficacy outcome measure for this group (using non-adjuvant-matched control data from the current study), LCP was compared between Groups B and A by Mann-Whitney test. The protocol-specified primary analysis of efficacy in Groups C, D, and E was comparison of LCP in each group to Group A by Mann-Whitney test with Bonferroni correction for multiple comparison. A post hoc secondary analysis of efficacy in terms of effect upon time to treatment was performed using a Mann-Whitney test with Bonferroni correction for multiple comparison, comparing each of Groups B, C, D, and E to Group A. The majority of immunological parameters were nonnormally distributed, and thus, unless detailed otherwise in the Supplemental Information, analyses of association between immunological parameters and continuous outcome variables were performed by Spearman’s rank correlation. The protocol-specified primary analysis for a correlate of protection, in the event that GIA EC50 data could not be estimated for every animal (as was the case here for a number of the animals in Groups C and E), was examination of the correlation between GIA at a fixed total IgG concentration and IVIG.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, five figures, and one table and can be found with this article online at http://dx.doi.org/10.1016/j.chom.2014.11.017.

AUTHOR CONTRIBUTIONS

A.D.D., G.C.B., K.M., C.A.L., K.A.E., Y.W., G.J.W., A.G.L., and S.J.D. designed and reviewed the study and interpreted the data; A.D.D., G.C.B., J.A.V., and A.J.S. performed the cellular immunoassay assays; A.D.D., A.D., K.M., K.H.L., K.H.M., K.A.H., C.A.L., and S.J.D. performed the humoral immunogenicity assays; A.D.D., C.C., S.J.B., J.J.I., D.G.W.A., A.V.T., Y.W., G.J.W., and S.J.D. prepared the proteins and various vaccine constructs; A.D.D., G.C.B., C.M.L., E.L.E., J.A.V., K.P.L., and Y.W. assisted with the malaria challenge and parasitological monitoring; L.A.L.-R. and J.T.M. undertook the clinical care of the Aotus monkeys; A.D.D. and S.J.D. performed the data and statistical analyses; and A.D.D. and S.J.D. led the study and wrote the paper with all the co-authors.

ACKNOWLEDGMENTS

The authors are grateful for the assistance of Adrian Hill, Julie Furze, the Viral Vector Core Facility and Adjuvant Bank (Jenner Institute, University of Oxford); David Stanton (Biophysical Instrument Facility, Department of Biochemistry, University of Oxford); Ly-Mee Yu and Doug Altman (Centre for Statistics in Medicine, University of Oxford); Julian Rayner (Wellcome Trust Sanger Institute, UK); Carmen Franco, Roxana Lescano, Jorge Nuñez, Meddy Santallalia, and Lorena Tapia (NAMRU-6, Peru); Olivo Miotti (Mahidol-Oxford Research Unit, Thailand); Yves Durocher for provision of HEK293E cells (CNRC-NRC, Canada); and Alfredo Nicosa (Okarito, Italy) for provision of the ChAd63 vector. A.D.D. held a Wellcome Trust Training Fellowship for Clinicians in Basic Sciences (grant number 089455/2/09/2). J.J.I. is a Wellcome Trust funded student on the Infection, Immunology and Translational Medicine PhD Programme (grant number 092873/z/10/2). C.C., S.J.B., and G.J.W. are supported by the Wellcome Trust (grant number 098051). The GIA work was supported by the PATH Malaria Vaccine Initiative and the Intramural Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases. This work was also funded in part by the University Challenge Seed Fund (Isis Innovation, University of Oxford) and by the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement number 242095 – EIViMalAR. G.L.G. is supported by training grant NIH/FIC 2D43 TW007393 awarded to NAMRU-6 by the Fogarty International Center of the US National Institutes of Health. S.J.D. holds a MRC Career Development Fellowship (grant number G1000527; this fellowship is jointly funded by the UK Medical Research Council [MRC] and the UK Department for International Development [DFID] under the MRC/DFID Concorde agreement) and is a Jenner Investigator and Lister Institute Research Prize Fellow. A.D.D., J.J.I., C.C., S.J.B., G.J.W., and S.J.D. are named on patent applications relating to PRR5H and/or other malaria vaccines. Some of the listed authors are either military service members (K.A.E., L.A.L.-R., J.T.M.) or employees of the US Government (G.C.B., C.M.L., J.A.V., K.P.L., A.G.L.). This work was prepared as part of their official duties. Title 17 U.S.C. §105 provides that “Copyright protection under this title is not available for any work of the United States Government.” Title 17 U.S.C. §101 defines a U.S. Government work as a work prepared by a military service member or employee of the US Government as part of that person’s official duties. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the US Government.

Received: May 17, 2014

Revised: September 11, 2014

Accepted: November 13, 2014

Published: January 14, 2015

REFERENCES

Agnanji, S.T., Leli, B., Fernandes, J.F., Abassolo, B.P., Methgo, B.G., Kalbwende, A.L., Adeginka, A.A., Mordmüller, B., Issifu, S., Krensner, P.G., et al.; RTS,S Clinical Trials Partnership (2012). A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367, 2284–2295.

Baum, J., Chen, L., Healer, J., Lopatnicki, S., Boyle, M., Triglia, T., Ehlen, F., Ralph, S.A., Beeson, J.G., and Cowman, A.F. (2009). Reticulocyte-binding protein homolog 5 - an essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum. Int. J. Parasitol. 39, 371–380.

Biswa, S., Dicks, M.D., Long, C.A., Remarque, E.J., Siani, L., Colloca, S., Cottingham, M.G., Holder, A.A., Gilbert, S.C., Hill, A.V., and Draper, S.J. (2011). Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1. PLoS ONE 6, e20977.

Biswa, S., Spencer, A.J., Forbes, E.K., Gilbert, S.C., Holder, A.A., Hill, A.V., and Draper, S.J. (2012). Recombinant viral vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection. J. Immunol. 188, 5041–5053.

Bustamante, L.Y., Bartholdson, S.J., Crosnier, C., Campos, M.G., Wanaguru, M., Nguon, C., Kwiatkowski, D.P., Wright, G.J., and Rayner, J.C. (2012). A
full-length recombinant Plasmodium falciparum PRfH5 protein induces inhibitory antibodies that are effective across common PRfH5 genetic variants. Vaccine 31, 373-379.

Collins, W.E., Galland, G.G., Sullivan, J.S., and Morris, C.L. (1994). Selection of different strains of Plasmodium falciparum for testing blood-stage vaccines in Aotus nancymai monkeys. Am. J. Trop. Med. Hyg. 51, 224-232.

Crosnier, C., Bustamante, L.Y., Bartholdson, S.J., Bei, A.K., Theron, M., Uchikawa, M., Mboup, S., Ndir, O., Kwiatkowski, D.P., Duraisingh, M.T., de Cassan, S.C., and Draper, S.J. (2013). Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets. Expert Rev. Vaccines 12, 365-378.

de Cassan, S.C., Forbes, E.K., Douglas, A.D., Millic, A., Singh, B., Gupta, P., Chauhan, V.S., Choudhry, P., Pardridge, W.M., Li, Y., and Draper, S.J. (2014). Neutralization of Plasmodium falciparum merozoite proteins by antibodies against PRfH5. J. Infect. Dis. 192, 245-258.

Douglas, A.D., Williams, A.R., Illingworth, J.J., Wellems, T.E. (2013). Various PRfH5 polymorphisms can support Plasmodium falciparum infection. J. Exp. Med. 212, 2142-2154.

Draper, S.J., Moore, A.C., Goodman, A.L., Holder, A.A., Gilbert, S.C., Hill, F., and Hill, A.V. (2010). Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? Hum. Vaccin. Immunother. 6, 706-714.

Durocher, Y., Perret, S., and Kamen, A. (2002). High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 30, E9.

Dutta, S., Sullivan, J.S., Grady, K.K., Haynes, J.D., Komisar, J., Batchelor, A.H., Soisson, L., Diggs, C.L., Heppner, D.G., Lanar, D.E., et al. (2009). High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS ONE 4, e8138.

Elias, S.C., Choudhry, P., de Cassan, S.C., Biswas, S., Collins, K.A., Halstead, F.D., Bliss, C.M., Ewer, K.J., Hodgson, S.H., Duncan, C.J., et al. (2014). Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection. Immunology 147, 628-644.

Ewer, K.J., O’Hara, G.A., Duncan, C.J., Collins, K.A., Sheehy, S.H., Reyes-Sandoval, A., Goodman, A.L., Edwards, N.J., Elias, S.C., Halstead, F.D., et al. (2013). Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat. Commun. 4, 2386.

Foquet, L., Hermens, C.C., van Gemert, G.J., Van Braeckel, E., Veenin, K.E., Sauvertain, R., Meulman, P., and Leroux-Roels, G. (2014). Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection. J. Clin. Invest. 124, 140-144.

Goodman, A.L., and Draper, S.J. (2010). Blood-stage malaria vaccines - recent progress and future challenges. Ann. Trop. Med. Parasitol. 104, 189-211.

Goodman, A.L., Epp, C., Moss, D., Holder, A.A., Wilson, J.M., Gao, G.P., Long, C.A., Remarque, E.J., Thomas, A.W., Amundola, V., et al. (2010). New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1. Infect. Immun. 78, 4601-4612.

Goodman, A.L., Forbes, E.K., Williams, A.D., de Cassan, S.C., Bauza, K., Biswas, S., Dicks, M.D., Leevelyn, D., Moore, A.C., et al. (2013). The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment. Sci Rep 3, 1706.

Gupta, S., Snow, R.W., Donnelly, C.A., Marsh, K., and Newbold, C. (1999). Immunity to non-cerebral severe malaria is acquired after one or two infections. Nat. Med. 5, 340-343.

Hayton, K., Gaur, D., Liu, A., Takahashi, J., Henschen, B., Singh, S., Lambert, L., Furuya, T., Bouttenot, R., Doll, M., et al. (2008). Erthrocyte binding protein PRfH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasion. Cell Host Microbe 4, 40-51.

Hayton, K., Dumoulin, P., Henschen, B., Liu, A., Papakrivos, J., and Wellems, T.E. (2013). Various PRfH5 polymorphisms can support Plasmodium falciparum invasion into the erythrocytes of monkey and rats. Mol. Biochem. Parasitol. 187, 103-110.

Hill, A.V. (2011). Vaccines against malaria. Philos. Trans. R. Soc. Lond. B Biol. Sci. 366, 2806-2814.

Hiisaeda, H., Saito, A., Reece, J.J., Kennedy, M.C., Long, C.A., Miller, L.H., and Stowers, A.W. (2002). Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys. J. Infect. Dis. 185, 657-664.

Hodgson, S.H., Choudhry, P., Elias, S.C., Milne, K.H., Rampling, T.W., Biswas, S., Poulton, I.D., Miura, K., Douglas, A.D., Alaine, D.G., et al. (2014). Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial. Mol. Ther. 22, 2142-2154.

Jones, T.R., Narum, D.L., Gozalo, A.S., Aguiar, J., Fuhrmann, S.R., Liang, H., Haynes, J.D., Moch, J.K., Lucas, C., Luu, T., et al. (2001). Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen. J. Infect. Dis. 183, 303-312.

Kennedy, M.C., Wang, J., Zhang, Y., Miles, A.P., Chitnis, F., Saul, A., Long, C.A., Miller, L.H., and Stowers, A.W. (2002). In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect. Immun. 70, 6948-6960.

Kester, K.E., Cummings, J.F., Ofori-Anyinam, O., Ockenhouse, C.F., Krzych, U., Moris, P., Schwenk, R., Nielsen, R.A., Debebe, Z., Pinelis, E., et al.; RTS,S Vaccine Evaluation Group (2009). Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J. Infect. Dis. 200, 337-346.

Lyon, J.A., Angov, E., Fay, M.P., Sullivan, J.S., Giroud, A.S., Robinson, S.J., Bergmann-Leitner, E.S., Duncan, E.H., Darko, C.A., Collins, W.E., et al. (2008). Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. PLoS ONE 3, e2830.

Mahdi Abdoul Hamid, M., Remarque, E.J., van Duivenvoorde, M.L., van der Werff, N., Walraven, F., Faber, B.W., Kocken, C.H., and Thomas, A.W. (2011). Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HTm protects against blood-stage challenge in rhesus macaques. PLoS ONE 6, e20547.

Manske, M., Miotta, O., Campino, S., Auborn, S., Almagro-Garcia, J., Maslen, G., O’Brien, J., Dijmde, A., Dounbo, O., Zongo, I., et al. (2012). Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature 487, 375-379.
Vaccine Immunol.
PfRH5, elicits detectable levels of invasion-inhibiting antibodies in humans. Duraisingh, M.T. (2013). Plasmodium falciparum merozoite surface antigen, Patel, S.D., Ahouidi, A.D., Bei, A.K., Dieye, T.N., Mboup, S., Harrison, S.C., and 31 antibodies is required for protection from clinical episodes of malaria. Vaccine Murungi, L.M., Kamuyu, G., Lowe, B., Bejon, P., Theisen, M., Kinyanjui, S.M., 379 malaria mortality between 1980 and 2010: a systematic analysis. Lancet Murray, C.J., Rosenfeld, L.C., Lim, S.S., Andrews, K.G., Foreman, K.J., Haring, 382 determination by the in vitro growth inhibition assay. Clin. Vaccine Immunol. Miura, K., Zhou, H., Diouf, A., Moret, S.E., Fay, M.P., Miller, L.H., Martin, L.B., Pierce, M.A., Ellis, R.D., Mullen, G.E., and Long, C.A. (2009). Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin. Vaccine Immunol. 17, 963–968.

Moorthy, V.S., Newman, R.D., and Okwo-Bele, J.M. (2013). Malaria vaccine technology roadmap. Lancet 382, 1700–1701.

Murray, C.J., Rosenfeld, L.C., Lim, S.S., Andrews, K.G., Foreman, K.J., Haring, D., Fullman, N., Naghavi, M., Lozano, R., and Lopez, A.D. (2012). Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379, 413–431.

Murungi, L.M., Kamuyu, G., Lowe, B., Bejon, P., Theisen, M., Kiryanjui, S.M., Marsh, K., and Osier, F.H. (2013). A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria. Vaccine 31, 3936–3942.

Patel, S.D., Ahouidi, A.D., Bei, A.K., Dieye, T.N., Moubou, S., Harrison, S.C., and Duraisingh, M.T. (2013). Plasmodium falciparum merozoite surface antigen, PRfH5, elicits detectable levels of invasion-inhibiting antibodies in humans. J. Infect. Dis. 208, 1679–1687.

Plotkin, S.A. (2010). Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17, 1055–1065.

Reddy, K.S., Pandey, A.K., Singh, H., Sahar, T., Emmanuel, A., Citnits, C.E., Chauhan, V.S., and Gaur, D. (2014). Bacterially expressed full-length recombinant Plasmodium falciparum RH5 protein binds erythrocytes and elicits potent strain-transcending parasite-neutralizing antibodies. Infect. Immun. 82, 152–164.

Remarque, E.J., Faber, B.W., Kocken, C.H., and Thomas, A.W. (2008). Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol. 24, 74–84.

Riley, E.M., and Stewart, V.A. (2013). Immune mechanisms in malaria: new insights in vaccine development. Nat. Med. 19, 168–178.

Sheehy, S.H., Duncan, C.J., Elias, S.C., Collins, K.A., Ewer, K.J., Spencer, A.J., Williams, A.R., Halstead, F.D., Moret, S.E., Miura, K., et al. (2011). Phase I clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol. Ther. 19, 2269–2276.

Sheehy, S.H., Duncan, C.J., Elias, S.C., Choudhary, P., Biswas, S., Halstead, F.D., Collins, K.A., Edwards, N.J., Douglas, A.D., Anagnostou, N.A., et al. (2012). ChAd63-MVA-vectorised blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol. Ther. 20, 2355–2368.

Sheehy, S.H., Douglas, A.D., and Draper, S.J. (2013). Challenges of assessing the clinical efficacy of asexually blood-stage Plasmodium falciparum malaria vaccines. Hum. Vaccin. Immunother. 9, 1831–1840.

Singh, S., Miura, K., Zhou, H., Muratova, O., Keegan, B., Miles, A., Martin, L.B., Saul, A.J., Miller, L.H., and Long, C.A. (2006). Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1); protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect. Immun. 74, 4573–4580.

Spring, M.D., Cummings, J.F., Ockenhouse, C.F., Dutta, S., Reidler, R., Angov, E., Bergmann-Leitner, E., Stewart, V.A., Bittner, S., Juompan, L., et al. (2009). Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS ONE 4, e5254.

Stowers, A.W., and Miller, L.H. (2001). Are trials in New World monkeys on the critical path for blood-stage malaria vaccine development? Trends Parasitol. 17, 415–419.

Stowers, A.W., Ciocce, V., Shimp, R.L., Lawson, M., Hui, G., Muratova, O., Kaslow, D.C., Robinson, R., Long, C.A., and Miller, L.H. (2001). Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial. Infect. Immun. 69, 1536–1546.

Stowers, A.W., Kennedy, M.C., Keegan, B.P., Saul, A., Long, C.A., and Miller, L.H. (2002). Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect. Immun. 70, 6961–6967.

Thera, M.A., Doumbo, O.K., Coulibaly, D., Laurens, M.B., Ouattara, A., Kone, A.K., Guindo, A.B., Traore, K., Traore, I., Kouriba, B., et al. (2011). A field trial to assess a blood-stage malaria vaccine. N. Engl. J. Med. 365, 1004–1013.

Tran, T.M., Ongoa, A., Coursen, J., Crosnier, C., Diouf, A., Huang, C.Y., Li, S., Doumbo, S., Doumtabe, D., Kone, Y., et al. (2014). Naturally acquired antibodies specific for Plasmodium falciparum apical membrane antigen 5 inhibit parasite growth and predict protection from malaria. J. Infect. Dis. 209, 789–798.

Villasis, E., Lopez-Perez, M., Torres, K., Gamboa, D., Neyra, V., Bendeju, J., Tricoche, N., Lobo, C., Vinetz, J.M., and Lustigman, S. (2012). Anti-Plasmodium falciparum invasion ligand antibodies in a low malaria transmission region, Loreto, Peru. Malar. J. 11, 361.

Wanaguru, M., Liu, W., Hahn, B.H., Rayner, J.C., and Wright, G.J. (2013). RH5-Basigin interaction plays a major role in the host tropism of Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 110, 20735–20740.

Weiss, W.R., Kumar, A., Jiang, G., Williams, J., Bostick, A., Conteh, S., Fryauff, D., Aguai, J., Singh, M., O’Hagan, D.T., et al. (2007). Protection of rhesus monkeys by a DNA prime/primovirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens. PLoS ONE 2, e1063.

Williams, A.R., Douglas, A.D., Miura, K., Illingworth, J.J., Choudhary, P., Murungi, L.M., Furze, J.M., Diouf, A., Miotto, O., Crosnier, C., et al. (2012). Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PRfH5 and other merozoite antigens. PLoS Pathog. 8, e1002991.

Wright, G.J., and Rayner, J.C. (2014). Plasmodium falciparum erythrocyte invasion: combining function with immune evasion. PLoS Pathog. 10, e1003943.